A review of the first year of Medicare coverage of erythropoietin.
Griffiths, Robert I
Date of Pub
Anderson, Gerald F; deLissovoy, Gregory; Eggers, Paul W; Greer, Joel W; Powe, Neil R; Watson, Alan J; Whelton, Paul K
Recombinant human erythropoietin (rHuEPO) is a new drug for treating anemia associated with end stage renal disease (ESRD).
In a study of rHuEPO diffusion, costs, and effectiveness, we analyze ESRD program data and all claims submitted to Medicare
for reimbursement of rHuEPO administered to ESRD dialysis patients. Access to rHuEPO was rapid and extensive during the first
year of Medicare coverage. Dosing of rHuEPO and achieved hematocrit were lower than expected based on the results of clinical
trials. rHuEPO cost Medicare $144 million in its first year. The analysis of insurance claims data allowed effective monitoring
of access, costs, and effectiveness of this new biotechnology.
Blacks : Diffusion of Innovation : Drug Costs : Erythropoietin/economics/therapeutic use : Female : Health Services Accessibility/statistics
& numerical data : Hemodialysis/economics/utilization : Human : Insurance, Pharmaceutical Services/statistics & numerical
data/utilization : Kidney Failure, Chronic/drug therapy/economics : Male : Medicare/statistics & numerical data/utilization
: Support, U.S. Gov't, Non-P.H.S. : Treatment Outcome : United States